Payers “Need A Bigger Boat” To Take On Pricing Like Sovaldi’s – Kaiser Permanente Exec
This article was originally published in The Pink Sheet Daily
Executive Summary
Kaiser Permanente’s Levine and Memorial Sloan Kettering’s Bach discuss approaches to restraining specialty drug costs at May 29 health care conference. CMS’ Tavenner suggests transparency and collaborating with industry on “appropriate use” can help manage costs of Gilead’s Sovaldi.
You may also be interested in...
India Set To Hear Sovaldi Patent Objections Case
India’s patent office has laid out a list of concerns on a pending Sovaldi application by Gilead Sciences – with the drug maker set to respond.
MSD India's Out-Of-The-Box Hep C Financing: How, Why And What Next?
Merck’s India unit has worked to refine a finance program for Hepatitis C treatments that could rapidly grow patient numbers by solving a financing issue that has bedeviled wider use.
Role Of Cost And Evidence In Value-Based Purchasing Highlighted By Zaltrap Price Adjustment
Sanofi’s recent reduction of the Zaltrap price after the Memorial Sloan-Kettering Cancer Center said it would not provide the drug to its advanced colorectal cancer patients due to its high cost relative to Avastin highlights the role cost and available clinical evidence will have as payers make value-based purchasing decisions.